Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study

Jesús Troya, Rocio Montejano, Pablo Ryan, Cristina Gómez, Mariano Matarranz, Alfonso Cabello, Francisco Vera, María Antonia Sepúlveda, Ignacio Santos, Gloria Samperiz, Pablo Bachiller, Vicente Boix, Pilar Barrufet, Miguel Cervero, José Sanz, Javier Solís, María Yllescas, Eulalia Valencia and on behalf of the GESIDA-8715 Study Group

PLOS ONE, 2018, vol. 13, issue 6, 1-16

Abstract: Background: Long-term combination antiretroviral therapy often results in toxicity/tolerability problems, which are one of the main reasons for switching treatment. Despite the favorable profile of raltegravir (RAL), data on its combination with abacavir/lamivudine (ABC/3TC) are scarce. Based on clinical data, we evaluated this regimen as a switching strategy. Design: Multicenter, non-controlled, retrospective study including all virologically suppressed HIV-1-infected patients who had switched to RAL+ABC/3TC. Methods: We evaluated effectiveness (defined as maintenance of HIV-1-RNA

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0198768 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 98768&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0198768

DOI: 10.1371/journal.pone.0198768

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().